Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway

被引:33
作者
Cheng, Dong-Dong [1 ]
Li, Shi-Jie [1 ]
Zhu, Bin [1 ]
Yuan, Ting [1 ]
Yang, Qing-Cheng [1 ]
Fan, Cun-Yi [1 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Orthoped, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China
关键词
POTENTIAL THERAPEUTIC TARGET; EIF5-MIMIC PROTEIN; PI3K/AKT/MTOR; ACTIVATION; PROLIFERATION; CHEMOTHERAPY; CARCINOMA; SURVIVAL; STRESS;
D O I
10.3892/or.2017.5890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteosarcoma is the most common malignant bone tumor in adolescents. The function of basic leucine zipper and W2 domains 2 (BZW2) in tumor progression has been reported. However, the role and mechanisms of BZW2 in osteosarcoma remain to be determined. The aim of the present study was to reveal the expression and biological functions of BZW2 in osteosarcoma and to elucidate the proximal mechanisms underlying these functions. The expression of BZW2 in osteosarcoma tissues and cell lines was assessed by qRT-PCR, western blotting and immunohistochemistry. BZW2 overexpression was detected in osteosarcoma cell lines. Clinically, BZW2 expression was higher in osteosarcoma tissues than in corresponding non-tumor tissues and was associated with advanced Enneking stage and tumor recurrence. The knockdown of BZW2 using siRNA inhibited osteosarcoma cell proliferation, colony-forming ability, and the cell cycle at the G2/M phase in vitro. Host signaling pathways affected by BZW2 were detected using a PathScan Intracellular Signaling Antibody Array kit. These data demonstrated that the knockdown of BZW2 suppresses protein phosphorylation in the Akt/mTOR signaling pathway. These observations suggest that BZW2 is upregulated and has a pro-tumor effect in osteosarcoma via activation of the Akt/mTOR signaling pathway and thus is a potential target for gene therapy.
引用
收藏
页码:2116 / 2122
页数:7
相关论文
共 26 条
[1]   Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics [J].
Costa, Ceu ;
Pereira, Sofia ;
Lima, Luis ;
Peixoto, Andreia ;
Fernandes, Elisabete ;
Neves, Diogo ;
Neves, Manuel ;
Gaiteiro, Cristiana ;
Tavares, Ana ;
Gil da Costa, Rui M. ;
Cruz, Ricardo ;
Amaro, Teresina ;
Oliveira, Paula A. ;
Ferreira, Jose Alexandre ;
Santos, Lucio L. .
PLOS ONE, 2015, 10 (11)
[2]   An update on chemotherapy for osteosarcoma [J].
Ferrari, Stefano ;
Serra, Massimo .
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) :2727-2736
[3]  
Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
[4]   E-cadherin interactome complexity and robustness resolved by quantitative proteomics [J].
Guo, Zhenhuan ;
Neilson, Lisa J. ;
Zhong, Hang ;
Murray, Paul S. ;
Zanivan, Sara ;
Zaidel-Bar, Ronen .
SCIENCE SIGNALING, 2014, 7 (354)
[5]   An integrated stress response regulates amino acid metabolism and resistance to oxidative stress [J].
Harding, HP ;
Zhang, YH ;
Zeng, HQ ;
Novoa, I ;
Lu, PD ;
Calfon, M ;
Sadri, N ;
Yun, C ;
Popko, B ;
Paules, R ;
Stojdl, DF ;
Bell, JC ;
Hettmann, T ;
Leiden, JM ;
Ron, D .
MOLECULAR CELL, 2003, 11 (03) :619-633
[6]   α-Solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt/mTOR pathway [J].
Hasanain, M. ;
Bhattacharjee, A. ;
Pandey, P. ;
Ashraf, R. ;
Singh, N. ;
Sharma, S. ;
Vishwakarma, A. L. ;
Datta, D. ;
Mitra, K. ;
Sarkar, J. .
CELL DEATH & DISEASE, 2015, 6 :e1860-e1860
[7]   Essential role of eIF5-mimic protein in animal development is linked to control of ATF4 expression [J].
Hiraishi, Hiroyuki ;
Oatman, Jamie ;
Haller, Sherry L. ;
Blunk, Logan ;
McGivern, Benton ;
Morris, Jacob ;
Papadopoulos, Evangelos ;
Gutierrez, Wade ;
Gordon, Michelle ;
Bokhari, Wahaj ;
Ikeda, Yuka ;
Miles, David ;
Fellers, John ;
Asano, Masayo ;
Wagner, Gerhard ;
Tazi, Loubna ;
Rothenburg, Stefan ;
Brown, Susan J. ;
Asano, Katsura .
NUCLEIC ACIDS RESEARCH, 2014, 42 (16) :10321-10330
[8]   mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review) [J].
Hu, Kai ;
Dai, Hai-Bo ;
Qiu, Zhi-Long .
ONCOLOGY REPORTS, 2016, 36 (03) :1219-1225
[9]   Osteosarcoma: Current Treatment and a Collaborative Pathway to Success [J].
Isakoff, Michael S. ;
Bielack, Stefan S. ;
Meltzer, Paul ;
Gorlick, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (27) :3029-U127
[10]   Osteosarcoma - Anatomic and histologic variants [J].
Klein, MJ ;
Siegal, GP .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (04) :555-581